These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37671259)

  • 1. Rapid effect of benralizumab in fulminant eosinophilic myocarditis in the setting of uncontrolled eosinophilic asthma.
    Goyack L; Garcha G; Shah R; Ortiz Gonzalez Y; Vollenweider M; Salimian M; Cheung W
    J Cardiol Cases; 2023 Sep; 28(3):100-104. PubMed ID: 37671259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
    Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
    Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis.
    Mümmler C; Mertsch P; Barnikel M; Haubner F; Schönermarck U; Grabmaier U; Schulze-Koops H; Behr J; Kneidinger N; Milger K
    J Asthma Allergy; 2024; 17():557-572. PubMed ID: 38860030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment.
    Davison J; Doe S
    Respir Med Case Rep; 2021; 34():101557. PubMed ID: 34877251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
    DuBuske L; Newbold P; Wu Y; Trudo F
    Allergy Asthma Proc; 2018 Sep; 39(5):345-349. PubMed ID: 30077185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression.
    Pelaia C; Crimi C; Benfante A; Caiaffa MF; Calabrese C; Carpagnano GE; Ciotta D; D'Amato M; Macchia L; Nolasco S; Pelaia G; Pellegrino S; Scichilone N; Scioscia G; Spadaro G; Valenti G; Vatrella A; Crimi N
    J Asthma Allergy; 2021; 14():163-173. PubMed ID: 33654413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Benralizumab in cases of eosinophilic granulomatosis with polyangiitis].
    Carrette A; Mercier V; Lelubre C; Peché R
    Rev Mal Respir; 2022 Sep; 39(7):621-625. PubMed ID: 35909008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An early Indian experience with benralizumab - A compendium on severe asthma cases: a case series.
    Talwar D; Yadav M; Maturu N; Sharma R; Meshram P; Das S
    F1000Res; 2023; 12():1225. PubMed ID: 38434642
    [No Abstract]   [Full Text] [Related]  

  • 10. Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report.
    Pham DN
    J Med Case Rep; 2021 Mar; 15(1):103. PubMed ID: 33673870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eosinophilic granulomatosis with polyangiitis developed during treatment with benralizmab for severe asthma: A case report and literature review.
    Sakabe M; Tobino K; Obata Y; Sogabe S; Uchida K; Murakami Y
    Respirol Case Rep; 2024 Jul; 12(7):e01431. PubMed ID: 38988828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use.
    Nolasco S; Campisi R; Intravaia R; Porto M; Pelaia C; Crimi N; Crimi C
    F1000Res; 2020; 9():637. PubMed ID: 32864107
    [No Abstract]   [Full Text] [Related]  

  • 15. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
    Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study).
    Martínez-Moragón E; García-Moguel I; Nuevo J; Resler G;
    BMC Pulm Med; 2021 Dec; 21(1):417. PubMed ID: 34922515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis.
    Guntur VP; Manka LA; Denson JL; Dunn RM; Dollin YT; Gill M; Kolakowski C; Strand MJ; Wechsler ME
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1186-1193.e1. PubMed ID: 33065367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis.
    Tsurumaki H; Matsuyama T; Ezawa K; Koga Y; Yatomi M; Aoki-Saito H; Chikamatsu K; Hisada T
    Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31277327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of eosinophilic chronic rhinosinusitis and eosinophilic otitis media using the anti-IL-5 receptor monoclonal antibody benralizumab: A case report.
    Kagoshima H; Hori R; Kojima T; Okanoue Y; Taguchi A; Yamamoto H; Hasebe K; Shoji K
    Respir Med Case Rep; 2020; 30():101135. PubMed ID: 32612919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment using corticosteroids in early phase of eosinophilic myocarditis with eosinophilic granulomatosis with polyangiitis.
    Hase H; Yamamoto T; Saito T; Yamazaki H; Kuno T; Tabei R; Kodaira M; Motoda H; Numasawa Y
    J Cardiol Cases; 2016 Dec; 14(6):177-180. PubMed ID: 30546689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.